Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Proteomic Analysis of Human Hepatocellular Carcinoma

This study has been completed.
Information provided by (Responsible Party):
Meng-Tzu Weng, Far Eastern Memorial Hospital Identifier:
First received: June 2, 2009
Last updated: February 4, 2016
Last verified: February 2016
This is a pilot study to evaluate the difference between the protein expression between hepatocellular carcinoma and tumor with vessel invasion in Asian patients with hepatocellular carcinoma.

Condition Intervention
Carcinoma, Hepatocellular
Procedure: Operation

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Basic Science
Official Title: Proteomic Analysis of Human Hepatocellular Carcinoma Associated With Portal Vein Thrombosis

Resource links provided by NLM:

Further study details as provided by Far Eastern Memorial Hospital:

Primary Outcome Measures:
  • Recurrence [ Time Frame: one year ] [ Designated as safety issue: No ]
    Evidence of clinically definite vascular invasion of hepatocellular carcinoma. Confirmed by operation. Compare the proteomic expression of tumor, non-tumor ans tumor tissue in vascular part.

Enrollment: 5
Study Start Date: February 2009
Study Completion Date: January 2010
Primary Completion Date: January 2010 (Final data collection date for primary outcome measure)
Intervention Details:
    Procedure: Operation
    Operation for clinically evaluated resectable hepatocelluar carcinoma. Compare the different expression of protein between tumor, non-tumor and tumor with vascular invasion part.

Ages Eligible for Study:   18 Years to 75 Years   (Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

Arm A: Hepatocellular carcinoma with vessel invasion:

  • hepatocellular carcionoma, pathologic diagnosed.
  • image documented vessel invasion, including portal vein thrombosis
  • eligible for surgical intervension.

Arm B: hepatocellular carcinoma without vessel invasion:

  • hepatocellular carcinoma, pathologic diagnosed or clinical diagnosed according to EASL criteria.
  • no vessel invasion on image.

Arm C: Healthy hepatitis carrier:

  • patients age >18 years old with hepatitis B or C
  • normal liver function.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01177631

Far Eastern Memorial Hospital
Taipei, Taiwan, 220
Sponsors and Collaborators
Far Eastern Memorial Hospital
  More Information

Responsible Party: Meng-Tzu Weng, Physician, Far Eastern Memorial Hospital Identifier: NCT01177631     History of Changes
Other Study ID Numbers: 97068 
Study First Received: June 2, 2009
Last Updated: February 4, 2016
Health Authority: Taiwan: Institutional Review Board

Keywords provided by Far Eastern Memorial Hospital:
Carcinoma, hepatocellular
Portal vein

Additional relevant MeSH terms:
Carcinoma, Hepatocellular
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Liver Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Liver Diseases processed this record on October 27, 2016